TABLE 3.
Percent susceptible for imipenem-relebactam and comparators by clonal group
| Agentb | Total (n = 203) | Sequence typed
|
ST131 subclonea
status |
Three-group P valuec | ||||
|---|---|---|---|---|---|---|---|---|
| ST131 (n = 68) | ST405 (n = 15) | ST648 (n = 15) | non-H30a (n = 141) | H30R1 (n = 22) | H30Rx (n = 40) | |||
| I-R | 180 (89) | 67 (99)** | 12 (80) | 14 (93) | 119 (84) | 22 (100) | 39 (98) | * |
| IPM | 90 (44) | 36 (53) | 11 (73)* | 11 (73)* | 56 (40) | 8 (36) | 26 (65) | * |
| MEM | 153 (75) | 51 (75) | 12 (80) | 14 (93) | 106 (75) | 15 (68) | 32 (80) | |
| ETP | 7 (3) | 1 (1.5) | 0 (0) | 0 (0) | 6 (4) | 0 (0) | 1 (2.5) | |
| GEN | 132 (65) | 47 (69) | 7 (47) | 10 (67) | 90 (64) | 13 (59) | 29 (73) | |
| TZP | 56 (28) | 22 (33) | 5 (33) | 5 (33) | 34 (24) | 4 (18) | 18 (45) | * |
| AMK | 163 (80) | 47 (69)** | 13 (87) | 12 (80) | 121 (86) | 20 (91) | 22 (55) | *** |
| LVX | 40 (20) | 4 (6)*** | 1 (7) | 3 (20) | 40 (28) | 0 (0) | 0 (0) | *** |
| TGC | 200 (99) | 68 (100) | 14 (93) | 15 (100) | 138 (98) | 22 (100) | 40 (100) | |
| CAZ | 19 (9) | 8 (12) | 2 (13) | 0 (0) | 12 (9) | 5 (23) | 2 (5) | |
| CL | 201 (99) | 67 (99) | 15 (100) | 15 (100) | 139 (99) | 22 (100) | 40 (100) | |
| MIN | 141 (69) | 58 (85)** | 5 (33)** | 10 (67) | 88 (62) | 20 (91) | 33 (83) | ** |
Non-H30, not a member of the ST131-H30R1 or H30Rx subclones (includes some ST131 strains); H30R1, fluoroquinolone resistance-associated subclone within ST131 (excludes H30Rx); H30Rx, extended-spectrum β-lactamase (ESBL) associated.
AMK, amikacin; CAZ, ceftazidime; CL, colistin; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; I-R, imipenem-relebactam; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TGC, tigecycline; TZP, piperacillin-tazobactam.
P value (from chi-square test) for three-group comparisons across ST131 subclone categories. *, P < 0.05; **, P < 0.01; ***, P ≤ 0.001.
P value (from chi-square test) for indicated ST versus all other isolates combined. *, P < 0.05; **, P < 0.01; ***, P ≤ 0.001.